Naoto Hirano

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Autoantibodies frequently detected in patients with aplastic anemia
    Naoto Hirano
    Dana Farber Cancer Institute, Department of Medical Oncology, 44 Binney St, Boston MA 02115, USA
    Blood 102:4567-75. 2003
  2. ncbi Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients
    Naoto Hirano
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 128:221-3. 2005
  3. ncbi Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity
    Naoto Hirano
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 107:1528-36. 2006
  4. ncbi Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses
    Naoto Hirano
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:2967-75. 2006
  5. ncbi Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia
    Naoto Hirano
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:2662-8. 2006
  6. ncbi Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help
    Marcus O Butler
    Department of Medical Oncology, Dana Farber Cancer Institute, Massachusetts, United States of America
    PLoS ONE 7:e30229. 2012
  7. ncbi Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell
    Makito Tanaka
    Department of Medical Oncology, Dana Farber Cancer Institute, USA
    Clin Cancer Res 17:5392-401. 2011
  8. ncbi Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells
    Marcus O Butler
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Sci Transl Med 3:80ra34. 2011
  9. ncbi Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application
    Michael S von Bergwelt-Baildon
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    Blood 99:3319-25. 2002
  10. ncbi IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells
    Osamu Imataki
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Immunol 188:1609-19. 2012

Research Grants

  1. Generation of Highly Avid Anti-Tumor CTL for Optimal Adoptive Immunotherapy
    Naoto Hirano; Fiscal Year: 2010
  2. Generation of Comprehensive Anti-Survivin T Cell Immunity Using an Artificial APC
    Naoto Hirano; Fiscal Year: 2007

Collaborators

Detail Information

Publications14

  1. ncbi Autoantibodies frequently detected in patients with aplastic anemia
    Naoto Hirano
    Dana Farber Cancer Institute, Department of Medical Oncology, 44 Binney St, Boston MA 02115, USA
    Blood 102:4567-75. 2003
    ..These results suggest that kinectin may be a candidate autoantigen that is involved in the pathophysiology of AA...
  2. ncbi Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients
    Naoto Hirano
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 128:221-3. 2005
    ..These results support the hypothesis that the epidemiology of AA is heterogeneous and suggest that anti-kinectin autoantibody titre may serve as a surrogate maker for the disease activity of AA...
  3. ncbi Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity
    Naoto Hirano
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 107:1528-36. 2006
    ..Therefore, engagement of the CD83L provides a unique signal to activated CD8+ T cells that could be exploited to generate long-lived antigen-specific cytotoxic T cells for the treatment of cancer and infection...
  4. ncbi Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses
    Naoto Hirano
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:2967-75. 2006
    ..Our engineered aAPC could serve as an "off-the-shelf" APC designed to constitutively express class I-restricted TAA peptides and could be used to generate effective T-cell responses to treat human disease...
  5. ncbi Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia
    Naoto Hirano
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:2662-8. 2006
    ....
  6. ncbi Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help
    Marcus O Butler
    Department of Medical Oncology, Dana Farber Cancer Institute, Massachusetts, United States of America
    PLoS ONE 7:e30229. 2012
    ..However, a mechanistic analysis of human CD4+ T cell help is largely lacking. Our goal was to elucidate the mechanisms of human CD4+ T cell help of CD8+ T cell proliferation using a novel in vitro model...
  7. ncbi Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell
    Makito Tanaka
    Department of Medical Oncology, Dana Farber Cancer Institute, USA
    Clin Cancer Res 17:5392-401. 2011
    ..In this article, we aimed to elucidate DP4-restricted CD4(+) T-cell responses against survivin in cancer patients...
  8. ncbi Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells
    Marcus O Butler
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Sci Transl Med 3:80ra34. 2011
    ..Therefore, this approach may broaden the availability of adoptive cell therapy to patients both alone and in combination with other therapeutic modalities...
  9. ncbi Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application
    Michael S von Bergwelt-Baildon
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    Blood 99:3319-25. 2002
    ..Therefore, they are an excellent source of professional APCs for immune assessment, antigen discovery, and antigen-specific immunotherapy...
  10. ncbi IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells
    Osamu Imataki
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Immunol 188:1609-19. 2012
    ..However, STAT3-mediated IL-21 signaling can supplement partial TCR signaling caused by the lack of CD8 association...
  11. ncbi Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21
    Sascha Ansén
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 14:6125-36. 2008
    ..In this study, we used a cell-based artificial antigen-presenting cell (aAPC) lacking a functional IL-21 receptor (IL-21R) to investigate the immunostimulatory properties of IL-21...
  12. ncbi Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell
    Marcus O Butler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 13:1857-67. 2007
    ..To overcome this, we sought to establish a clinical grade culture system that can reproducibly generate antigen-specific cytotoxic T lymphocytes (CTL)...
  13. ncbi A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles
    Marcus O Butler
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Int Immunol 22:863-73. 2010
    ..Our results suggest that K562-based aAPC may serve as a translatable platform to generate both antigen-specific CD8(+) CTL and CD4(+) T(h)...
  14. ncbi The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells
    Britta Maecker
    Head, Molecular Tumor Biology and Tumor Immunology University of Cologne, Joseph Stelzmann Str 9 Haus 16, 50924 Cologne, Germany
    Blood 102:3287-94. 2003
    ..These findings form the basis of a phase 1 clinical trial exploring a DNA-based vector encoding CYP1B1 for widely applicable cancer immunotherapy conducted at the Dana-Farber Cancer Institute...

Research Grants3

  1. Generation of Highly Avid Anti-Tumor CTL for Optimal Adoptive Immunotherapy
    Naoto Hirano; Fiscal Year: 2010
    ..Since cancer treatment with these cells has demonstrated promising results in recent clinical trials, we propose to further improve this system to produce stronger cancer-fighting cells that can attack cancer more effectively. ..
  2. Generation of Comprehensive Anti-Survivin T Cell Immunity Using an Artificial APC
    Naoto Hirano; Fiscal Year: 2007
    ....